ABS-101 / Absci Corp - LARVOL DELTA

Absci Announces First Participants Dosed in Phase 1 Clinical Trial of ABS-101, a Potential Best-In-Class anti-TL1A Antibody for the Treatment of Inflammatory Bowel Disease (GlobeNewswire) - "Absci Corporation...announced that the first healthy volunteers have been dosed in a randomized, placebo-controlled Phase 1 study evaluating ABS-101, an investigational anti-TL1A antibody engineered with Absci’s generative AI platform....The study is expected to enroll approximately 40 healthy adult participants. The primary endpoint is safety and tolerability, with PK, PD, and immunogenicity serving as secondary endpoints. The Phase 1 interim data readout is expected in the second half of 2025."

P1 data • Trial status • Inflammatory Bowel Disease

Absci Reports Business Updates and Third Quarter 2024 Financial and Operating Results (GlobeNewswire) - "ABS-101 (potential best-in-class anti-TL1A antibody):...Absci continues to advance ABS-101 through IND-enabling studies, plans to initiate Phase 1 clinical studies for ABS-101 in the first half of 2025, and continues to expect an interim data readout in the second half of 2025....Research and development expenses were $18.0 million for the three months ended September 30, 2024 compared to $11.0 million for the three months ended September 30, 2023. This increase was primarily driven by increased lab operations, including direct costs associated with IND-enabling studies for ABS-101, and an increase in stock compensation expense."

New P1 trial • P1 data • Immunology • Inflammatory Bowel Disease

Absci Reports Business Updates and First Quarter 2024 Financial and Operating Results (GlobeNewswire) - "Absci plans to share additional preclinical data, including data from non-human primate studies, for this program in the next few months. Absci expects to initiate Phase 1 clinical studies for ABS-101 in early 2025, with an interim data readout expected in the second half of 2025."

New P1 trial • P1 data • Preclinical • Immunology • Inflammatory Bowel Disease